


# Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: E. Korkmaz Yurtolu and M. Zora, *Org. Biomol. Chem.*, 2025, DOI: 10.1039/D5OB01892G.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

## ARTICLE

Facile one-pot synthesis of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines

Esra Korkmaz Yurtoglu and Metin Zora\*

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

A straightforward and efficient one-pot protocol for the synthesis of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines is reported. When subjected to the reaction with ethylenediamine in refluxing dioxane, bis- $\alpha,\beta$ -alkynic ketones, i.e. 1,9-diarylnona-2,7-diyne-1,9-diones, afford 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines. Generation of three new C–N bonds, along with one C–C bond cleavage, during the reaction leads to the construction of unknown fused five- and six-membered heterocyclic ring systems. The reaction goes through an imidazoline intermediate. Similarly, the reaction of bis- $\alpha,\beta$ -alkynic ketones with 1,2-propylenediamine produces 2-methyl-substituted hexahydroimidazo[1,2-*a*]pyridines. The skeletal diversity of the synthesized hexahydroimidazo[1,2-*a*]pyridines may be of use in pharmaceutical and medicinal chemistry as the new and novel molecular entities and structural leads.


## Introduction

Imidazo[1,2-*a*]pyridine (IP) (**1**) and derivatives have emerged as valuable structural features in pharmaceutical and material science because of their easy availability, great stability and a wide range of biological and material properties they possess (Scheme 1).<sup>1</sup> In fact, IP consists of five-membered imidazole moiety fused with six-membered pyridine ring and constitutes one of the most important bridgehead (ring junction) N-containing heterocyclic cores due to its common appearance in the structures of numerous natural products and drugs.<sup>2</sup> IPs have been reported to display a diverse range of biological properties, including antiulcer, anticonvulsant, antifungal, antiviral, anticancer, antiprotozoal, antibacterial, anti-inflammatory, anthelmintic, analgesic, antituberculosis, antipyretic, antiepileptic, and antitumor activities.<sup>3</sup> They also act at various targets including enzymes (CDK, MEK, PI3K and GSK3), receptors (ALK-5, KDR, mGluR5, 5HT, MHC-R1, H3, D4 and GABAA) and infectious agents (HCMV, VZV, HSV-1, CXCR4 and CCR5).<sup>3,4</sup> Moreover, they form the core structures of a range of drugs, including *Zolpidem* (hypnotic, used in the treatment of insomnia), *Necopidem* and *Saripidem* (sedative and anxiolytic agent), *Microprofen* (prostanoid signaling modulator, analgesic and NSAID) and *Olprinone* (for treatment of acute heart failure) (Scheme 2).<sup>5,6</sup> Importantly, benzo-fused and partially reduced derivatives also exhibit interesting biological activities. For instance, compound **I** is a useful potassium ion channel modulator for treatment of neurological disorders.<sup>7</sup> Compound **II** shows cytotoxicity to the human cancer cell line MCF-7.<sup>8</sup> Compound **III** has a high affinity for a peripheral benzodiazepine receptor and displays anticancer activity as well (Scheme 2).<sup>9</sup> So, over the years, many fruitful, mild and productive strategies have been developed for the

synthesis of IPs and new variants continue to emerge due to their immense importance.<sup>10</sup>




**Scheme 1** Structures of imidazo[1,2-*a*]pyridine (IP) and 2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridine (2,3,5,6,7,8-HIP)



**Scheme 2** Representative examples of imidazo[1,2-*a*]pyridine containing compounds

Department of Chemistry, Faculty of Arts and Science, Middle East Technical University, 06800 Ankara, Turkey. E-mail: zora@metu.edu.tr





**Scheme 3** Synthetic approaches for the synthesis of 2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines and their octahydro- and benzo-fused derivatives


Sometimes, as compared to the parent compounds, partially reduced derivatives may be more important from the point of view of biological activity and material properties. Notably, hexahydroimidazo[1,2-*a*]pyridines (HIPs) are less known.<sup>11</sup> In particular, 2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines (2,3,5,6,7,8-HIPs) (**2**) (Scheme 1), called also 1,7-dizabicyclo[4.3.0]non-6-enes, are very limited and, to the best of our knowledge, only a few examples of these molecules are available (Scheme 3).<sup>12-15</sup> As shown by Mikhlina, Vorob'eva and Yakhontov,

catalytic hydrogenation of 2-(pyridin-2-ylamino)ethanol provided 2-(3,4,5,6-tetrahydropyridin-2-ylamino)ethanol, which, upon chlorination with thionyl chloride, followed by intramolecular cyclization, generated 2,3,5,6,7,8-HIP (Scheme 3a).<sup>12</sup> Anderson research group displayed that the reaction of valerolactam (piperidin-2-one) with 2-aminoethanol in the presence of hydrochloric acid afforded 2-(3,4,5,6-tetrahydropyridin-2-ylamino)ethanol, which, upon reaction with thionyl chloride, produced 2,3,5,6,7,8-HIP (Scheme 3b).<sup>13</sup> On the other hand, Yamamoto research group first prepared 6-ethoxy-2,3,4,5-tetrahydropyridine by the reaction of valerolactam with triethyloxonium tetrafluoroborate. Then its reaction with aziridine afforded 6-aziridin-1-yl-2,3,4,5-tetrahydropyridine. Finally, its rearrangement with molecular iodine or trimethylsilyl iodide gave 2,3,5,6,7,8-HIP (Scheme 3c).<sup>14</sup> Similarly, Birman research group prepared 6-methoxy-2,3,4,5-tetrahydropyridine derivative by the reaction of valerolactam with dimethyl sulfate, which, upon reaction with 2-aminoethanol hydrochloride, followed by treatment with thionyl chloride, yielded 2,3,5,6,7,8-HIP (Scheme 3d).<sup>15</sup> It is noteworthy as a close study that Liu and coworkers synthesized


alkyne-tethered benzimidazoles from the corresponding 5-hexynoic acid methyl ester, *o*-phenylenediamine and aryl iodides, and then investigated their intramolecular cyclizations under few conditions.<sup>16</sup> These reactions led to formation of 1-alkylidene-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridines or their iodo-substituted derivatives depending upon the reagents (Scheme 3e).<sup>16</sup> Easwar and coworkers investigated the reactions of cyclic Morita-Baylis-Hillman ketones with ethylenediamine derivatives (Scheme 3f).<sup>17</sup> The conjugate addition of diamine, followed by retro-Mannich reaction, yielded an imidazolyl-substituted 1,3-diketone intermediate, in which the condensation of secondary amine with ketone afforded octahydroimidazo[1,2-*a*]pyridine derivatives. Notably, the value of 2,3,5,6,7,8-HIPs has been underrepresented in medicinal chemistry due to the lack of efficient synthetic strategies. An ever-growing aspect of these studies is to find novel derivatives, which may provide a new mode of action for the treatment of a specific disease. Accordingly, there is a continuous need to develop new methodologies for the synthesis of such compounds since it may increase their significance and potential in the related fields.

Vasilevsky and Alabugin reported that the reaction of diaryl-substituted  $\alpha,\beta$ -alkynic ketones with ethylenediamine (EDA) led to formation of 2-aryl-4,5-dihydro-1*H*-imidazoles and aryl methyl ketones (Scheme 4a).<sup>18</sup> In fact, this reaction first proceeds by the sequential bis-conjugate addition of EDA, yielding an imidazoline intermediate, and then by the concerted retro-Mannich reaction of imidazoline to afford 4,5-dihydro-1*H*-imidazole and aryl methyl ketone.<sup>18</sup> Due to our ongoing interest in the synthesis of new heterocyclic molecules as potential pharmaceuticals and scaffolds,<sup>19</sup> we have anticipated that the reaction of bis- $\alpha,\beta$ -alkynic ketones **1** (namely 1,9-diarylnona-2,7-diyne-1,9-diones) with EDA might provide dihydroimidazolyl-substituted  $\alpha,\beta$ -alkynic ketones **2** (i.e. 6-(4,5-dihydro-1*H*-imidazol-2-yl)hex-2-yn-1-ones) by a similar mechanism, which could then undergo intramolecular conjugate addition to yield 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines **3** (Scheme 4b). To the best of our knowledge, this approach has not been utilized previously for the synthesis of such hexahydroimidazo[1,2-*a*]pyridines **3**. To our delight, we have found that when treated with EDA in refluxing dioxane, bis- $\alpha,\beta$ -alkynic ketones **1** produced the unknown 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines **3** in one-pot manner (Scheme 4b). Notably, the formation of these molecules by the intramolecular cyclization of linear precursors also represents a valuable tool in terms of the synthetic methodology. Herein, we report the preliminary results of this study.

(a) Study of the Vasilevsky and Alabugin research groups



(b) This study: Synthesis of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines




**Scheme 4** Strategies for the synthesis of 4,5-dihydro-1*H*-imidazoles and 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines



## Results and discussion

Initially, we synthesized the necessary starting materials, i.e. symmetrical and unsymmetrical bis- $\alpha,\beta$ -alkynic ketones **1** and **6**, respectively, according to similar literature protocols as depicted in Scheme 5.<sup>20</sup> When subjected to Sonogashira coupling with aryloyl chlorides under palladium catalysis, 1,6-heptadiyne afforded doubly-coupled symmetrical bis- $\alpha,\beta$ -alkynic ketones **1** and mono-coupled  $\alpha,\beta$ -alkynic ketones **5**. Notably, bis- $\alpha,\beta$ -alkynic ketones **1** were obtained as the major products from these reactions. We synthesized 16 derivatives of bis- $\alpha,\beta$ -alkynic ketones **1**, the yields of which ranged between 33 and 64%. Mono-coupled  $\alpha,\beta$ -alkynic ketones **5** were also resulted from these reactions as the minor products. Unfortunately, their formation could not be prevented. The yields of mono-coupled  $\alpha,\beta$ -alkynic ketones **5** varied between 6-48% yields. When needed, mono-coupled  $\alpha,\beta$ -alkynic ketones **5** could be subjected once again to Sonogashira coupling with the same aryloyl chlorides to generate symmetrical bis- $\alpha,\beta$ -alkynic ketones **1**. On the other hand, Sonogashira coupling of  $\alpha,\beta$ -alkynic ketones **5** with different aryloyl chlorides afforded unsymmetrical bis- $\alpha,\beta$ -alkynic ketones **6** (Scheme 5). By employing this approach, we synthesized three derivatives of unsymmetrical bis- $\alpha,\beta$ -alkynic ketones **6**, the yields of which were varied between 40-72%. For the identities and yields of the synthesized mono- and bis- $\alpha,\beta$ -alkynic ketones **1**, **5** and **6**, see Supplementary Information.



**Scheme 5** Synthesis of bis- $\alpha,\beta$ -Alkynic Ketones

With bis- $\alpha,\beta$ -alkynic ketones in hand, we next investigated their reactions with EDA. In order to test the reaction and optimize the conditions, we examined the reaction of 1,9-diphenylnona-2,7-diyne-1,9-dione (**1a**) with EDA as the model reaction as depicted in Table 1. We first tried the reaction with 1.0, 2.0 and 3.0 equivalents of EDA in refluxing dioxane, which afforded 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridine (HIP) **3a** in 41-54% yields (Table 1, entries 1-3). Among them, the highest yield (54%) of product **3a** was obtained with 2.0 equiv. of EDA. When the same reaction was carried out at room temperature, no any products were obtained (Table 1, entry 4). We tested the reaction in the concentrated condition and pressure tube as well (Table 1, entries 5 and 6), but the yields of **3a** (37 and 40%, respectively) did not improve. Then we tried the reaction in refluxing toluene by using 1.0 and 2.0 equivalents of EDA, generating HIP **3a** in 48 and 53% yields, respectively (Table 1, entries 7 and 8). Notably, the reactions with 2.0 equiv of EDA in dioxane and


toluene at reflux conditions furnished HIP **3a** in very close yields (54% vs 53%). After these results, we continued the reactions with 2.0 equivalents of EDA. The reaction in refluxing *p*-xylene furnished HIP **3a** in 45% yield (Table 1, entry 9). Notably, longer reaction time at high temperature somewhat decreased the yield of HIP **3a** (35%), possibly due to decomposition (Table 1, entry 10). Subsequently, we performed the reaction in acetonitrile and chloroform, yielding HIP **3a** in 31 and 37% yields, respectively (Table 1, entries 11 and 12). We tested the reaction in alcohols and water as well (Table 1, entries 13-18). Among them, the highest yield (44%) of product **3a** was observed in methanol. The reactions in butanol and water did not produce any products (Table 1, entries 17 and 18). At last, we tried the reaction in *N,N*-dimethylformamide and dimethyl sulfoxide at 120 °C (Table 1, entries 19 and 20). The reaction in DMF produced the expected product **3a** in 35% yield, but that in DMSO did not give any products. It should be mentioned that during the optimization reactions in Table 1, if the cyclization product HIP **3a** formed, a methyl ketone derivative **7a**, namely acetophenone, was also obtained from these reactions in varying yields (11-43%). This is because the formation of dihydroimidazole moiety of intermediate **2a** occurs along with the formation of acetophenone (**7a**) as it will be discussed in the mechanism. In summary, the generality and substrate coverage of the reaction was demonstrated by employing 1.0 and 2.0 equivalents of bis- $\alpha,\beta$ -alkynic ketones and EDA, respectively, in refluxing dioxane.

Interestingly, HIP **3a** was obtained as a single isomer from these reactions although in principle it could result as the *E* or *Z* isomer or a mixture of both isomers. We took NOESY spectrum of **3a** in order to assign the configuration of the exo double bond (see Supplementary information). Spectrum showed a nuclear overhauser effect (NOE) arising from a through-space interaction between vinylic hydrogen and methylene hydrogens adjacent to tertiary nitrogen atom, as depicted in Table 1. Therefore, the configuration of the exo double bond of **3a** was defined as the *E*.

Afterwards, we explored the scope and limitations of the methodology by employing a variety of bis- $\alpha,\beta$ -alkynic ketones **1** to access 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines **3** (Table 2). It should be mentioned that hexahydroimidazo[1,2-*a*]pyridines **3** are generally quite polar compounds and therefore their characterization through column chromatography has been laborious, but we have succeeded their isolation in most cases. In fact, all reactions proceeded smoothly and provided the expected hexahydroimidazo[1,2-*a*]pyridines **3**. Importantly, during the course of the reactions, three new C-N bonds were formed along with one C-C bond cleavage, which enabled the formation of new fused five- and six-membered heterocyclic ring systems **3**. Overall, we synthesized 16 derivatives of hexahydroimidazo[1,2-*a*]pyridines **3**, the yields of which changed from 17 to 56%. Halogen bonds play an important role in medicinal chemistry because of their ability to delicately influence drug-target interactions, such as binding affinity, selectivity, structural rigidity and conformation control, and absorption, distribution, metabolism and excretion (ADME) properties of a drug.<sup>21</sup> In particular, fluorine atoms can significantly affect the biological activity, stability, and pharmacokinetics of drugs.<sup>22</sup> Therefore, we synthesized eight derivatives (**3i-p**) of halogen-containing hexahydroimidazo[1,2-*a*]pyridines in 21-56% yields. During the synthesis of hexahydroimidazo[1,2-*a*]pyridines **3**,




## ARTICLE

**Table 1** Optimization of the reaction conditions<sup>a,b</sup>

Entry	Equiv of EDA <sup>c</sup>	Solvent	Temp. (°C)	Time (h)	Yield of 3a (%)	Yield of 7a (%) <sup>d</sup>
1	1.0	Dioxane	101	5	51	<i>n.d.</i>
2	2.0	Dioxane	101	4	54	41
3	3.0	Dioxane	101	7	41	<i>n.d.</i>
4	2.0	Dioxane	rt	20	–	–
5 <sup>e</sup>	2.0	Dioxane	101	5	37	12
6 <sup>f</sup>	2.0	Dioxane	101	5	40	<i>n.d.</i>
7	1.0	Toluene	110	3	48	<i>n.d.</i>
8	2.0	Toluene	110	3	53	20
9	2.0	<i>p</i> -Xylene	138	2	45	29
10	2.0	<i>p</i> -Xylene	138	6	35	<i>n.d.</i>
11	2.0	MeCN	82	6	31	<i>n.d.</i>
12	2.0	CHCl <sub>3</sub>	62	6	37	13
13	2.0	MeOH	65	6	44	11
14	2.0	EtOH	78	2	39	40
15	2.0	<i>n</i> -Propanol	97	7	15	<i>n.d.</i>
16	2.0	Isopropanol	82.5	8	16	<i>n.d.</i>
17	2.0	<i>n</i> -BuOH	117	4	–	–
18	2.0	Water	100	7	–	–
19 <sup>g</sup>	2.0	DMF	120	6	35	43
20	2.0	DMSO	120	4.5	–	–

<sup>a</sup>Reactions were performed on a scale of 0.25 mmol of 1,9-diphenylnona-2,7-diyne-1,9-dione (**1a**) in 5 mL of solvent under indicated conditions unless noted. For workup and purification, see Experimental section and Supplementary information. <sup>b</sup>Isolated yields. <sup>c</sup>Equivalency is given according to that of the starting bis- $\alpha,\beta$ -alkynyl ketone **1a**. <sup>d</sup>*n.d.* = Yield not determined. <sup>e</sup>This reaction was carried out in a pressure tube by using 2.5 mL of solvent. <sup>f</sup>This reaction was performed in a pressure tube. <sup>g</sup>This reaction was performed in 2 mL of solvent.



**Table 2** Synthesis of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines<sup>a,b,c,d,e</sup>View Article Online  
DOI: 10.1039/D5OB01892G


<sup>a</sup>Reactions were performed on a scale of 0.25 mmol of bis- $\alpha,\beta$ -alkynic ketones **1** and 0.50 mmol of ethylenediamine in 5 mL of dioxane at reflux. For workup and purification, see Experimental section. <sup>b</sup>Isolated yields. <sup>c</sup>For the identities of aryl methyl ketones **7**, see Supplementary information. <sup>d</sup>*n.d.* = Yield not determined. <sup>e</sup>Yield of the product obtained from the reaction performed on a 2.40 mmol scale of bis- $\alpha,\beta$ -alkynic ketones **1a** (see Supplementary information).

aryl methyl ketones **7** were also resulted from these reactions in varying amounts (15–60%) (Table 2). Notably, aryl methyl ketones have emerged as the valuable precursors and intermediates for the synthesis of a variety of medicinally important heterocycles.<sup>23</sup> It is noteworthy that the expected products hexahydroimidazo[1,2-*a*]pyridine **3** and aryl methyl ketone **7** from a particular starting bis- $\alpha,\beta$ -alkynic ketone **1** should form in a one-to-one ratio as evident from their formation mechanism (Scheme 6). However, we were not able to obtain these products in a one-to-one ratio from the column chromatography. Possibly, they decomposed and/or underwent side

reactions to some extent. A similar situation was observed by Vasilevsky and Alabugin during the isolation of 4,5-dihydro-1*H*-imidazoles along with aryl methyl ketones (Scheme 4a).<sup>18</sup> It is noteworthy that we carried out the reaction of bis- $\alpha,\beta$ -alkynic ketones **1a** on a relatively larger scale (2.40 mmol) as well, which generated hexahydroimidazo[1,2-*a*]pyridine **3a** in 43% yield, along with acetophenone (**7a**) in 33% yield (Table 2). Although yields are slightly lower than those in a small scale, it certainly indicates the practical utility of the method as a synthetic tool.



## ARTICLE

**Table 3** Synthesis of 2-methyl-substituted 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines<sup>a,b,c</sup>

<sup>a</sup>Reactions were performed on a scale of 0.25 mmol of bis- $\alpha,\beta$ -alkynic ketones **1** and 0.50 mmol of 1,2-propylenediamine in 5 mL of dioxane at reflux. For workup and purification, see Experimental section. <sup>b</sup>Isolated yields. <sup>c</sup>For the identities of aryl methyl ketones **7**, see Supplementary information.


In order to further widen the array of products, we also examined the reaction of several bis- $\alpha,\beta$ -alkynic ketones **1** with 1,2-propylenediamine (PDA) (1,2-diaminopropane) (Table 3). Although, in principle, these reactions could produce two possible products, they afforded 2-methyl-substituted 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines **8**, along with aryl methyl ketones **7**. Notably, 3-methyl-substituted hexahydroimidazo[1,2-*a*]pyridines **9** did not form in these reactions or formed in very low yields, which escaped from the isolation. The position of the methyl group was determined by an NOESY measurement. As depicted in Table 3, NOESY spectrum of **8a** showed NOE interactions between vinylic hydrogen and diastereotopic methylene hydrogens (see also Supplementary information), proving the indicated structure of **8a**. In fact, we synthesized five derivatives of 2-methyl-substituted HIPs **8** in 23–45% yields, along with the corresponding aryl methyl ketones **7** in 8–65% yields (Table 3). It should be noted that since the racemic (achiral) PDA was used in these reactions, the racemic (achiral) products **8** were obtained.

We investigated the reactions of few unsymmetrical bis- $\alpha,\beta$ -alkynic ketones **6** with EDA as well. However, these reactions were

not clean and produced a mixture of inseparable products, from which the expected products could not be isolated purely and their clean NMR spectra could not be obtained. Consequently, we did not devote much effort to the reactions of unsymmetrical bis- $\alpha,\beta$ -alkynic ketones **6** with EDA.

The proposed mechanism for the synthesis of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines **3** is given in Scheme 6. First, intermolecular conjugate (Michael-like) addition of EDA to bis- $\alpha,\beta$ -alkynic ketone **1** generates  $\beta$ -enaminone **10**. Then  $\beta$ -enaminone **10** undergoes a 5-*exo-trig* cyclization to afford imidazolidine **11** via intramolecular conjugate (Michael-like) addition of primary amine functionality to enaminone moiety. Subsequently, intermediate **11** experiences a retro-Mannich fragmentation via a six-membered transition state to produce dihydroimidazolyl-substituted  $\alpha,\beta$ -alkynic ketone **2** along with aryl methyl ketone **7** after tautomerization. It should be noted that formation of  $\alpha,\beta$ -alkynic ketones **2** and aryl methyl ketones **7** in these reactions is consistent with the findings of earlier researchers.<sup>18</sup> Finally, 6-*exo-dig* cyclization through another intramolecular conjugate (Michael-like) addition at **2** provides the corresponding hexahydroimidazo[1,2-*a*]pyridine **3** (Scheme 6).






**Scheme 6** Mechanism proposed for the formation of 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines

It is noteworthy to mention that in the reaction performed by Vasilevsky and Alabugin and their coworkers, the polarized alkyne ( $C\equiv C$ ) unit is fully cleaved by the formation of final products as depicted in Scheme 4a.<sup>18</sup> However, in our reaction, such a cleavage of one alkyne moiety creates an advantage because the resulting intermediate **2** (dihydroimidazolyl-substituted  $\alpha,\beta$ -alkynic ketone) serves as the starting material for the synthesis of 2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridine derivatives **3** (Scheme 4b and Scheme 6). We performed few control experiments to capture the intermediate product **2a**. Therefore, we carried out the reaction of **1a** at various temperatures (rt, 40 and 60 °C) in THF, methanol, dioxane and toluene. At rt and 40 °C, only the first conjugate addition step (**1a** → **10a**) took place in these solvents, as concluded from <sup>1</sup>H NMR analysis of crude reaction mixtures, and we did not see any evidence for the formation of any cyclic intermediate product. At 60 °C, a similar trend was observed in dioxane and toluene, producing only the conjugate addition product. However, in methanol at 60 °C, hexahydroimidazo[1,2-*a*]pyridine **3a** was also formed in addition to conjugate addition product, but in low amount (37%), and we could not capture the intermediate product **2a** in this reaction. In brief, in these control experiments, we did not see any spectroscopic evidence the formation of intermediate **2a**. When the reaction was carried out at 100 °C, such as in dioxane, final product **3a** was resulted along with aryl methyl ketone **7a**. Presumably, the second conjugate addition (**10a** → **11a**) requires higher temperatures and proceeds around 100 °C. Furthermore, once imidazolidine **11a** is formed, it undergoes an immediate fragmentation to yield intermediate **2a** and aryl methyl ketone **7a**. So far, our observations are consistent with the findings of Vasilevsky and Alabugin on similar systems.<sup>18</sup> In general, their experimental results and DFT calculations showed that first conjugate addition of EDA to  $\alpha,\beta$ -alkynic ketones (as in **1** → **10**) easily happens at room temperature while second intramolecular conjugate addition (as in **10** → **11**) obligates higher temperatures such as 100 °C although it is a favored 5-*exo-trig* closure according to Baldwin rules.<sup>24</sup> Moreover, the activation barriers for such 5-*exo-trig* ring closures have been calculated to be substantial (>26-30 kcal/mol). They also found that the calculated activation barrier for the fragmentation step (as in **11** → **2** + **7**) is slightly lower than that for the 5-*exo-trig* cyclization (as in **10** → **11**), indicating that second intramolecular conjugate addition (i.e. **10** → **11**) is the rate-limiting step in this process. So, for our case, we conclude that when the reaction reaches the sufficient temperature (approximately 100 °C), the intermediate product **2** forms and

immediately experiences another conjugate addition between its secondary amine and  $\alpha,\beta$ -alkynic ketone functionalities to give hexahydroimidazo[1,2-*a*]pyridine **3**. Notably, the activation barrier for **2** → **3** is much lower than those for **10** → **11** and **11** → **2**. Since the intermediate **2** contains both nucleophilic and electrophilic centers in its structure, it enables a very fast intramolecular cyclization via 6-*exo-dig* closure to produce the final product **3** (Scheme 6). This might be the reason why we could not observe the formation of intermediate **2**.

The proposed mechanistic rationale for the formation of 2-methyl-substituted hexahydroimidazo[1,2-*a*]pyridines **8** is shown in Scheme 7. The reaction of bis- $\alpha,\beta$ -alkynic ketones **1** with PDA first produces in situ tautomeric dihydroimidazolyl-substituted  $\alpha,\beta$ -alkynic ketones **12** and **13**, which then give rise to formation of 2- and 3-methyl-substituted HIPs **8** and **9**, respectively, by a similar mechanism given in Scheme 6. Notably, secondary nitrogen atom in **12** is farther from methyl substituent; so it is more available as a nucleophile for the intramolecular conjugate addition to afford the final HIP **8**. However, in **13**, methyl group increases the steric hindrance around the nearby secondary nitrogen atom, making it significantly less accessible for intramolecular conjugate addition to lead to final HIP **9** although it is expected to be slightly more electron rich (nucleophilic) due to the +I effect of adjacent methyl substituent, as compared to that in **12**. In brief, steric accessibility is more dominant for nucleophilicity, and these reactions afforded 2-methyl-substituted HIPs **8** through the intermediacy of **12** as the major or single product as expected (Scheme 7).



**Scheme 7** Mechanistic rationale proposed for the formation of 2-methyl-substituted 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines

## Conclusions

In summary, we have uncovered a new and novel reaction of bis- $\alpha,\beta$ -alkynic ketones, i.e. 1,9-diarylnona-2,7-diyne-1,9-diones. When treated with ethylenediamine in dioxane at reflux, bis- $\alpha,\beta$ -alkynic ketones have produced 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines in low to moderate yields. During the course of the reaction, three new C–N bonds form along with one C–C bond cleavage, resulting in the formation of unknown fused five- and six-membered heterocyclic ring systems. The reaction proceeds via an intermediacy of five-membered imidazolidine ring. A similar trend has been observed in the reaction of bis- $\alpha,\beta$ -alkynic ketones with 1,2-propylenediamine, where only 2-methyl-substituted 5-alkylidene-2,3,5,6,7,8-hexahydroimidazo[1,2-*a*]pyridines were obtained. The skeletal diversity of the synthesized



hexahydroimidazo[1,2-*a*]pyridine frame may provide many new nitrogen-based heterobicyclic systems for drug discovery and development.

## Experimental

**General procedure for the synthesis of 1,9-diarylnona-2,7-diyne-1,9-diones **1** (Scheme 5).** To a stirred solution of the proper aryloyl chloride (3.0 mmol) in THF (12 mL) under argon was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.03 mmol) and Et<sub>3</sub>N (1.8 mmol), and the resulting mixture was stirred for 10 min at room temperature and CuI (0.03 mmol) was added. After stirring the reaction mixture for another 10 min, 1,6-heptadiyne (**4**) (1.5 mmol) was added slowly, and the stirring at room temperature continued until the end of the reaction (The progress of the reaction was monitored by routine TLC analysis for the disappearance of 1,6-heptadiyne (**4**) using 9:1 hexane/ethyl acetate as the eluent). After the reaction was over, the solvent was removed on a rotary evaporator, and ethyl acetate (50 mL) and a saturated aqueous solution of NH<sub>4</sub>Cl solution (50 mL) were added. After the layers were separated, the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over MgSO<sub>4</sub> and evaporated on a rotary evaporator to give the crude product, which was purified by flash chromatography on silica gel using 9:1 hexane/ethyl acetate as the eluent to afford the corresponding symmetrical 1,9-diarylnona-2,7-diyne-1,9-dione **1** and 1-arylocta-2,7-diyne-1-one **5**.

**General procedure for the synthesis of 1-aryl-2-(2,3,7,8-tetrahydroimidazo[1,2-*a*]pyridin-5(6*H*)-ylidene)ethanones **3** (Table 2).** To a stirred solution of the proper 1,9-diarylnona-2,7-diyne-1,9-dione **1** (0.25 mmol) in dioxane (5.0 mL) under argon was added ethylenediamine (0.50 mmol), and the resulting mixture was refluxed until the end of the reaction (The progress of the reaction was monitored by routine TLC analysis for the disappearance of bis- $\alpha,\beta$ -alkynic ketone **1** using 4:1 hexane/ethyl acetate as the eluent). After the reaction was over, the solvent was removed on a rotary evaporator, and the resulting crude product was purified by flash chromatography on silica gel using 4:1 hexane/ethyl acetate, followed by 1:1 methanol/ethyl acetate, as the eluent to afford the corresponding 1-aryl-2-(2,3,7,8-tetrahydroimidazo[1,2-*a*]pyridin-5(6*H*)-ylidene)ethanone **3** and aryl methyl ketone **7**.

## Conflicts of interest

There are no conflicts to declare.

## Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. Experimental procedures, spectroscopic data and copies of NMR spectra for starting materials and products (PDF). See DOI: <https://doi.org/10.1039/.....>

## Acknowledgements

We thank the Scientific and Technological Research Council of Turkey (TUBITAK, Grant No. 123Z511) for financial support of this research and the Middle East Technical University (METU) for providing spectroscopic facilities.

## Notes and references

- (a) N. Punna, S. S. Jadvav, A. Ramaraju, R. R. Donthiri and C. R. Reddy, Bicyclic 5-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: One Extra Heteroatom 1:0. In *Comprehensive Heterocyclic Chemistry IV*; eds. D. StC Black, J. Cossy, C. V. Stevens, G. Masson, Elsevier Science, 2022, Vol. 11, ch. 11.09, pp. 596–621; (b) L. A. P. Ferreira, L. Caruso, N. F. Nadur, D. P. Franco, G. L. S. Sousa, R. B. Lacerda and A. E. Kummerle, Imidazo[1,2-*a*]pyridines in Medicinal Chemistry: Recent Advances in Synthesis and Biological Activities, *ACS Omega*, 2026, **11**, 2348–2383.
- A. Deep, R. K. Bhatia, R. Kaur, S. Kumar, U. K. Jain, H. Singh, S. Batra, D. Kaushik and P. K. Deb, Imidazo[1,2-*a*]pyridine Scaffold as Prospective Therapeutic Agents, *Current Topics in Med. Chem.*, 2017, **17**, 238–250.
- J. Panda, B. P. Raiguru, M. Mishra, S. Mohapatra and S. Nayak, Recent Advances in the Synthesis of Imidazo[1,2-*a*]pyridines: A Brief Review, *ChemistrySelect*, 2022, **7**, No. e202103987.
- C. Enguehard-Gueiffier and A. Gueiffier, Recent Progress in the Pharmacology of Imidazo[1,2-*a*]pyridines, *Mini-Reviews in Med. Chem.*, 2007, **7**, 888–899.
- A. K. Bagdi, S. Santra, K. Monir and A. Hajra, Synthesis of imidazo[1,2-*a*]pyridines: a decade update, *Chem. Commun.*, 2015, **51**, 1555–1575.
- K. Pericherla, P. Kaswan, K. Pandey and A. Kumar, Recent Developments in the Synthesis of Imidazo[1,2-*a*]pyridines, *Synthesis*, 2015, **47**, 887–912.
- A. B. Fulp and X. Wang, Asymmetric Benzimidazoles and Related Compounds as Potassium Channel Modulators, WO2005002503 A2, 2005.
- W. Deady and T. Rodemann, Reduced Benzimidazo[2,1-*a*]isoquinolines. Synthesis and Cytotoxicity Studies, *Aust. J. Chem.*, 2001, **54**, 529–534.
- T. Okubo, R. Yoshikawa, S. Chaki, S. Okuyamac and A. Nakazato, Design, synthesis, and structure–activity relationships of novel tetracyclic compounds as peripheral benzodiazepine receptor ligands, *Bioorg. Med. Chem.*, 2004, **12**, 3569–3580.
- For recent examples, see. (a) A. J. Zahara, B. E. Haines and S. M. Wilkerson-Hill, Programmed Heterocycle Synthesis Using Halomucononitriles as Pyridinimine Precursors, *Org. Lett.*, 2024, **26**, 2976–2981; (b) Y. Zhang, R. Chen, Z. Wang, L. Wang and Y. Ma, I<sub>2</sub>-Catalyzed Three-Component Consecutive Reaction for the Synthesis of 3-Aroylimidazo[1,2-*a*]-*N*-Heterocycles, *J. Org. Chem.*, 2021, **86**, 6239–6246; (c) F. Vuillermet, J. Bourret and G. Pelletier, Synthesis of Imidazo[1,2-*a*]pyridines: Triflic Anhydride-Mediated Annulation of 2*H*-Azirines with 2-Chloropyridines, *J. Org. Chem.*, 2021, **86**, 388–402; (d) H. Okai, K. Tanimoto, R. Ohkado and H. Iida, Multicomponent Synthesis of Imidazo[1,2-*a*]pyridines: Aerobic Oxidative Formation of C–N and C–S Bonds by Flavin–Iodine-Coupled Organocatalysis, *Org. Lett.*, 2020, **22**, 8002–8006; (e) S. Cacchi, A. Ciogli, N. Demitri, G. Fabrizi, F. Ghirga, A. Goggiamani, A. Iazzetti and D. Lamba, Copper-



- Catalyzed C–N Bond Formation via C–H Functionalization: Facile Synthesis of Multisubstituted Imidazo[1,2-*a*]pyridines from *N*-(2-Pyridinyl)enaminones, *Synthesis*, 2018, **50**, 3513–3519.
- 11 For selected examples, see: (a) S. O. Kushch, M. V. Goryaeva, E. A. Surnina, Y. V. Burgart, M. A. Ezhikova, M. I. Kodess, P. A. Slepukhin and V. I. Saloutin, Multicomponent Domino Reactions for the Synthesis of Variable Hydrogenated Imidazo[1,2-*a*]pyridines, *Asian J. Org. Chem.*, 2022, **11**, No. e202100709; (b) H. Tan and Y. Wang, Facile Synthesis of Novel Hexahydroimidazo[1,2-*a*]pyridine Derivatives by One-Pot, Multicomponent Reaction under Ambient Conditions, *ACS Comb. Sci.*, 2020, **22**, 468–474; (c) H. G. O. Alvim, J. R. Correa, J. A. F. Assumpção, W. A. da Silva, M. O. Rodrigues, J. L. de Macedo, M. Fioramonte, F. C. Gozzo, C. C. Gatto and B. A. D. Neto, Heteropolyacid-Containing Ionic Liquid-Catalyzed Multicomponent Synthesis of Bridgehead Nitrogen Heterocycles: Mechanisms and Mitochondrial Staining, *J. Org. Chem.*, 2018, **83**, 4044–4053; (d) K. M. Wang, Y. L. Ma, X. R. Lin, S. J. Yan and J. Lin, Regioselective synthesis of pyrrolo[1,2-*a*]imidazoles and imidazo[1,2-*a*]pyridines, *RSC Adv.*, 2015, **5**, 36472–36479; (e) R. L. Wang, P. Zhu, Y. Lu, F. P. Huang and X. P. Huia, Brønsted Acid-Catalyzed Four-Component Cascade Reaction: Facile Synthesis of Hexahydroimidazo[1,2-*a*]pyridines., *Adv. Synth. Catal.*, 2013, **355**, 87–92.
- 12 E. E. Mikhlina, V. Ya. Vorob'eva and L. N. Yakhontov, The Reduction of 1,7-Diazabicyclo[4,3,0]non-6-ene and of 2,3-Dihydroimidazo[1,2-*a*]pyridine as Azacyclic Compounds with an Amidine Structure, *Chem. Heterocyclic Compounds*, 1970, **6**, 457–459.
- 13 J. Rokach, P. Hamel, N. R. Hunter, G. Reader and C. S. Rooney, Cyclic Amidine Inhibitors of Indolamine *N*-Methyltransferase, *J. Med. Chem.*, 1979, **22**, 237–247.
- 14 H. Yamamoto and K. Maruoka, Regioselective Carbonyl Amination Using Diisobutylaluminum Hydride., *J. Am. Chem. Soc.*, 1981, **103**, 4186–4194.
- 15 V. B. Birman, X. Li and Z. Han, Nonaromatic Amidine Derivatives as Acylation Catalysts, *Org. Lett.*, 2007, **9**, 37–40.
- 16 (a) X. Zhang, Y. Zhou, H. Wang, D. Guo, D. Ye, Y. Xu, H. Jiang and H. Liu, Silver-catalyzed intramolecular hydroamination of alkynes in aqueous media: efficient and regioselective synthesis for fused benzimidazoles, *Green Chem.*, 2011, **13**, 397–405; (b) X. Zhang, Y. Zhou, H. Wang, D. Guo, D. Ye, Y. Xu, H. Jiang and H. Liu, An Effective Synthetic Entry to Fused Benzimidazoles via Iodocyclization, *Adv. Synth. Catal.*, 2011, **353**, 1429–1437.
- 17 S. Sharma, A. K. Jha and Srinivasan Easwar, A retro-Mannich mediated transformation of Morita–Baylis–Hillman ketones to saturated imidazo[1,2-*a*]pyridines, *Org. Chem. Front.*, 2024, **11**, 3137–3150.
- 18 (a) S. Roy, M. P. Davydova, R. Pal, K. Gilmore, G. A. Tolstikov, S. F. Vasilevsky and I. V. Alabugin, Dissecting Alkynes: Full Cleavage of Polarized C≡C Moiety via Sequential Bis-Michael Addition/Retro-Mannich Cascade, *J. Org. Chem.*, 2011, **76**, 7482–7490; For the full cleavage of C≡C bonds, see also: (b) S. F. Vasilevsky, D. S. Baranov, V. I. Mamatyuk, Y. V. Gatilov, and I. V. Alabugin, An Unexpected Rearrangement That Disassembles Alkyne Moiety Through Formal Nitrogen Atom Insertion between Two Acetylenic Carbons and Related Cascade Transformations: New Approach to Sampangine Derivatives and Polycyclic Aromatic Amides, *J. Org. Chem.*, 2009, **74**, 6143–6150; (c) S. F. Vasilevsky, M. P. Davydova, V. I. Mamatyuk, N. Tsvetkov, A. Hughes, D. S. Baranov and I. V. Alabugin, Full Cleavage of C≡C Bond in Electron-Deficient Alkynes via Reaction with Ethylenediamine, *Aust. J. Chem.*, 2017, **70**, 421–429.
- 19 (a) Y. Kelgokmen, Y. Cayan and M. Zora, Zinc Chloride Mediated Synthesis of 1,4-Oxazepines from *N*-Propargylic β-Enaminones, *Eur. J. Org. Chem.*, 2017, **47**, 7167–7178; (b) Y. Kelgokmen and M. Zora, Synthesis of 1,4-Thiazepines, *J. Org. Chem.*, 2018, **83**, 8376–8379; (c) Y. Kelgokmen and M. Zora, A new strategy for the synthesis of pyridines from *N*-propargylic β-enaminothiones, *Org. Biomol. Chem.*, 2019, **17**, 2529–2541; (d) E. Korkmaz and M. Zora, Synthesis of 3-[(4-Nitrophenyl)thio]-Substituted 4-Methylene-1-pyrrolines from *N*-Propargylic β-Enaminones, *J. Org. Chem.*, 2020, **85**, 4937–4950; (e) N. Kanova, B. A. Dundar, Y. Kelgokmen and M. Zora, One-Pot Synthesis of 2-Acetyl-1*H*-pyrroles from *N*-Propargylic β-Enaminones via Intermediacy of 1,4-Oxazepines, *J. Org. Chem.*, 2021, **86**, 6289–6304; (f) N. E. Aksakal and M. Zora, InCl<sub>3</sub>-Catalyzed One-Pot Synthesis of Pyrrolo/Indolo- and Benzooxazepino-Fused Quinoxalines, *ACS Omega*, 2024, **9**, 33251–33260; (g) E. S. Yilmaz, K. Kaya and M. Zora, Facile synthesis of unknown 6,7-dihydrofuro[3,4-*c*]pyridines and 3,4-diaryloxy pyridines from *N*-homopropargylic β-enaminones, *Org. Biomol. Chem.*, 2025, **23**, 2133–2141.
- 20 (a) R. J. Cox, D. J. Ritson, T. A. Dane, J. Berge, J. P. H. Charmant and A. Kantacha, Room temperature palladium catalysed coupling of acyl chlorides with terminal alkynes, *Chem. Commun.*, 2005, **8**, 1037–1039; (b) S. Cacchi, G. Fabrizi and E. Filisti, *N*-Propargylic β-Enaminones: Common Intermediates for the Synthesis of Polysubstituted Pyrroles and Pyridines, *Org. Lett.*, 2008, **10**, 2629–2632; (c) S. Karabiyikoglu, Y. Kelgokmen and M. Zora, Facile Synthesis of Iodopyridines from *N*-Propargylic β-Enaminones via Iodine-Mediated Electrophilic Cyclization, *Tetrahedron*, 2015, **71**, 4324–4333; (d) G. Albano and L. A. Aronica, Acyl Sonogashira Cross-Coupling: State of the Art and Application to the Synthesis of Heterocyclic Compounds, *Catalysts*, 2020, **10**, No. 25; (e) P. A. Volkov, K. O. Khrapova, I. A. Bidusenko, A. A. Telezhkin, E. Yu. Schmidt, A. I. Albanov and B. A. Trofimov, Chemoselective cross-coupling of terminal propargylamines with (het)aroyl chlorides: synthesis of β-aminoacetylenic ketones bearing aromatic and heteroaromatic substituents, *Russ. Chem. Bull.*, 2022, **71**, 1514–1518; (f) P. A. Volkov, K. O. Khrapova, A. A. Telezhkin, I. A. Bidusenko, E. Yu. Schmidt, A. I. Albanov and Boris A. Trofimov, Pd/Cu-Catalyzed Cross-Coupling of Densely Substituted Propargylamines with Aromatic Acyl Chlorides Followed by the Treatment with a Base: Access to Dihydro-3*H*-Pyrrol-3-Ones, *Adv. Synth. Catal.*, 2023, **365**, 53–67.
- 21 (a) M. Hernandez, S. M. Cavalcanti, D. R. Moreira, W. de Azevedo Junior and A. C. Leite, Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design, *Curr. Drug Targets*, 2010, **11**, 303–314; (b) N. K. Shinada, A. G. de Brevern and P. Schmidtke, Halogens in Protein–Ligand Binding Mechanism: A Structural Perspective, *J. Med. Chem.*, 2019, **62**, 9341–9356.
- 22 (a) J. Wang, M. Sanchez-Rosello, J. L. Acena, C. del Pozo, A. E. Sorochinsky, S. Fustero, V. A. Soloshonok and H. Liu, Fluorine in



- Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011), *Chem. Rev.*, 2014, **114**, 2432–2506; (b) E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly and N. A. Meanwell, Applications of Fluorine in Medicinal Chemistry, *J. Med. Chem.*, 2015, **58**, 8315–8359.
- 23 (a) S. Rajai-Daryasarei, M. H. Gohari and N. Mohammadi, Reactions involving aryl methyl ketone and molecular iodine: a powerful tool in the one-pot synthesis of heterocycles, *New J. Chem.*, 2021, **45**, 20486–20518; (b) S. Mohammed, J. S. West and M. J. Mitton-Fry, Aryl Methyl Ketones: Versatile Synthons in the Synthesis of Heterocyclic Compounds, *SynOpen*, 2022, **6**, 110–131; (c) D. S. Yang, X. L. Chen and A. X. Wu, Review of application of the I<sub>2</sub> and dimethyl sulfoxide combined reagent system to aryl methyl ketones for diverse transformations, *Org. Chem. Front.*, 2024, **11**, 2665–2692.
- 24 (a) J. E. Baldwin, Rules for ring closure, *J. Chem. Soc. Chem. Commun.*, 1976, **18**, 734–736; (b) I. Alabugin, K. Gilmore and M. Manoharan, Rules for Anionic and Radical Ring Closure of Alkynes, *J. Am. Chem. Soc.*, 2011, **133**, 12608–12623; (c) K. Gilmore and I. V. Alabugin, Cyclizations of Alkynes: Revisiting Baldwin's Rules for Ring Closure, *Chem. Rev.*, 2011, **111**, 6513–6556.

View Article Online  
DOI: 10.1039/D5OB01892G



## Data Availability Statement

The data supporting this article have been included as part of the supplementary information (SI).

